Table 3.
Response to cilta-cel
| Full cohort N = 20 |
ADC exposed∗ N = 13 |
Bispecific exposed∗ N = 7 |
|
|---|---|---|---|
| Overall response rate,† % (95% CI) | 60.0 (36.1-80.9) | 61.5 (31.6-86.1) | 57.1 (18.4-90.1) |
| Best response, rate, n (%) | |||
| Stringent complete response | 1 (5.0) | 1 (7.7) | 0 |
| Complete response | 5 (25.0) | 4 (30.8) | 1 (14.3) |
| Very good partial response | 5 (25.0) | 3 (23.1) | 2 (28.6) |
| Partial response | 1 (5.0) | 0 | 1 (14.3) |
| Minimal response‡ | 1 (5.0) | 0 | 1 (14.3) |
| Stable disease | 3 (15.0) | 2 (15.4) | 1 (14.3) |
| Progressive disease | 3 (15.0) | 3 (23.1) | 0 |
| Not evaluable‡,§ | 1 (5.0) | 0 | 1 (14.3) |
| ≥VGPR | 11 (55.0) | 8 (61.5) | 3 (42.9) |
| Median duration of response (95% CI), mo | 11.5 (7.9-NE) | 11.5 (7.9-NE) | 8.2 (4.4-NE) |
| Median time to first response (range), mo | 0.95 (0.9-6.0) | 0.97 (0.9-5.1) | 0.92 (0.9-6.0) |
| Median time to best response (range), mo | 2.22 (0.9-9.9) | 2.58 (0.9-9.9) | 1.41 (0.9-7.0) |
| MRD negativity, n (%) | |||
| No. of patients evaluable at 10−5 | 10 | 7 | 3 |
| Rate, n (%) | 7 (70.0) | 5 (71.4) | 2 (66.7) |
Response assessed by validated computerized algorithm.
ADC, antibody-drug conjugate; CI, confidence interval; MRD, minimal residual disease; NE, not evaluable; VGPR, very good partial response.
∗
Classification is based on the last anti-BCMA therapy used if patients received >1 anti-BCMA therapy; 1 patient received BsAb before ADC and another 2 different types of ADC sequentially.
†
Sum of sCR + CR + VGPR + partial response.
‡
Patients died prior to confirmed disease evaluation.
§
Patient died at day 17 and was therefore not assessed.